- Home
- KLRS vs BTTC Comparison
KLRS vs BTTC Comparison
Compare KLRS & BTTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- BTTC
- Stock Information
- Founded
- KLRS 2019
- BTTC 1990
- Country
- KLRS United States
- BTTC Malaysia
- Employees
- KLRS N/A
- BTTC N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- BTTC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KLRS Health Care
- BTTC Health Care
- Exchange
- KLRS Nasdaq
- BTTC Nasdaq
- Market Cap
- KLRS 46.0M
- BTTC 40.5M
- IPO Year
- KLRS N/A
- BTTC N/A
- Fundamental
- Price
- KLRS $6.31
- BTTC $3.04
- Analyst Decision
- KLRS Strong Buy
- BTTC
- Analyst Count
- KLRS 3
- BTTC 0
- Target Price
- KLRS $21.50
- BTTC N/A
- AVG Volume (30 Days)
- KLRS 147.9K
- BTTC 33.0K
- Earning Date
- KLRS 11-12-2025
- BTTC 01-01-0001
- Dividend Yield
- KLRS N/A
- BTTC N/A
- EPS Growth
- KLRS N/A
- BTTC N/A
- EPS
- KLRS N/A
- BTTC 0.72
- Revenue
- KLRS N/A
- BTTC $2,719,480.00
- Revenue This Year
- KLRS N/A
- BTTC N/A
- Revenue Next Year
- KLRS N/A
- BTTC N/A
- P/E Ratio
- KLRS N/A
- BTTC $4.34
- Revenue Growth
- KLRS N/A
- BTTC 2.04
- 52 Week Low
- KLRS $2.14
- BTTC $2.81
- 52 Week High
- KLRS $12.90
- BTTC $39.00
- Technical
- Relative Strength Index (RSI)
- KLRS 57.79
- BTTC N/A
- Support Level
- KLRS $6.04
- BTTC N/A
- Resistance Level
- KLRS $7.07
- BTTC N/A
- Average True Range (ATR)
- KLRS 0.66
- BTTC 0.00
- MACD
- KLRS 0.08
- BTTC 0.00
- Stochastic Oscillator
- KLRS 64.94
- BTTC 0.00
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About BTTC Black Titan Corporation Ordinary Shares
Black Titan Corp is engaged in software implementation and training. It provides consulting services and Human Resource and Payroll solutions.